Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer

Cancer Immunology Research

Volumn 3, Issue 11, 2015, Pages 1207-1217

  Rautela, Jai ^a,b,c   Baschuk, Nikola ^a   Slaney, Clare Y ^a,b,c   Jayatilleke, Krishnath M ^a   Xiao, Kun ^a   Bidwell, Bradley N ^b   Lucas, Erin C ^b   Hawkins, Edwin D ^b   Lock, Peter ^a   Wong, Christina S ^d   Chen, Weisan ^a   Anderson, Robin L ^b,c   Hertzog, Paul J ^e   Andrews, Daniel M ^e   Möller, Andreas ^d   Parker, Belinda S ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; METASTASIS; METASTASIS FREE SURVIVAL; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPINE METASTASIS; TUMOR CELL INOCULATION; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; C57BL MOUSE; DEFICIENCY; DISEASE COURSE; FEMALE; IMMUNOLOGY; KNOCKOUT MOUSE; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SECONDARY; TRANSPLANTATION;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; DISEASE PROGRESSION; FEMALE; INTERFERON TYPE I; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION;

EID: 84957579051     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0065     Document Type: Article

References (41)

1. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
2. Liotta LA, Kohn E. Anoikis: Cancer and the homeless cell. Nature 2004; 430:973-4.
3. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
4. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGFbeta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
5. Fidler IJ. The pathogenesis of cancermetastasis: The seed and soil' hypothesis revisited. Nat Rev Cancer;3:453-8.
6. Slaney CY, Rautela J, Parker BS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res 2013;73:5852-7.
7. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012;18:1224-31.
8. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
9. Nagano Y, Kojima Y. [Inhibition of vaccinia infection by a liquid factor in tissues infected by homologous virus]. C R Seances Soc Biol Fil 1958; 152:1627-9.
10. Gresser I, Maury C, Brouty-Boye D.Mechanism of the antitumour effect of interferon in mice. Nature 1972;239:167-8.
11. Balkwill F, Watling D, Taylor-Papadimitriou J. Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int J Cancer 1978;22:258-65.
12. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9.
13. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrowmicrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
14. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013;13:145-9.
15. Davie SA, Maglione JE, Manner CK, Young D, Cardiff RD, MacLeod CL, et al. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res 2007;16:193-201.
16. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007;178:7540-9.
17. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, TymmsMJ, Hamilton JA, et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and altersmacrophage responses. Proc Natl Acad Sci U S A 1995;92:11284-8.
18. Aslakson CJ, Miller FR. Selective events in themetastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
19. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-70.
20. Quan PC, Ishizaka T, Bloom BR. Studies on themechanism of NK cell lysis. J Immunol 1982;128:1786-91.
21. Eckhardt BL, Parker BS, Van Laar RK, Restall CM, Natoli AL, Tavaria MD, et al. Genomic analysis of a spontaneous model of breast cancermetastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005; 3:1-13.
22. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: Standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 2001;8:1131-5.
23. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirusmiddle T oncogene: A transgenic mousemodel for metastatic disease. Mol Cell Biol 1992;12:954-61.
24. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26.
25. Eyob H, Ekiz HA, Derose YS, Waltz SE, WilliamsMA, Welm AL. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov 2013;3:751-60.
26. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 2009;69:5996-6004.
27. Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012;36:166-74.
28. Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 2012;1:1027-37.
29. Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, Seillet C, Chopin M, Vandenberg CJ, et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun 2014; 5:4539.
30. McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, et al. Distinct and complementary functions of MDA5 and TLR3 in poly (I:C)-mediated activation of mouse NK cells. J Exp Med 2009; 206:2967-76.
31. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74.
32. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu Rev Immunol 2013;31:227-58.
33. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005;42:501-10.
34. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174:4465-9.
35. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521-30.
36. Deauvieau F, Ollion V, Doffin AC, Achard C, Fonteneau JF, Verronese E, et al. Human natural killer cells promote cross-presentation of tumor cellderived antigens by dendritic cells. Int J Cancer 2015;136:1085-94.
37. Baschuk N, Rautela J, Parker BS. Bone specific immunity and its impact on metastasis. BoneKEy 2015;4:665.
38. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: Finding common ground. Cancer Metastasis Rev 2013;32:449-64.
39. AndrewsDM, SmythMJ.Apotential role for RAG-1 inNK cell development revealed by analysis of NK cells during ontogeny. Immunol Cell Biol 2010;88:107-16.
40. Karo JM, Schatz DG, Sun JC. The RAG recombinase dictates functional heterogeneity and cellular fitness in natural killer cells. Cell 2014;159:94-107.
41. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22.